5-methyl-1,3-oxazole-4-carbonyl Chloride | 914637-76-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-methyl-1,3-oxazole-4-carbonyl Chloride
• CAS: 914637-76-6
• 化学式: C₅H₄ClNO₂
• 分子量: 145.545
• InChiKey: KEZILNYHDBBHBM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  43.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  5-甲基-1,3-异恶唑-4-甲酸 在 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 生成 5-methyl-1,3-oxazole-4-carbonyl Chloride
  参考文献：
  名称：

  Synthesis and biological activity of novel 4,4-difluorobenzazepine derivatives as non-peptide antagonists of the arginine vasopressin V1A receptor

  摘要：

  To find potent and selective antagonists of the arginine vasopressin (AVP) V-1A receptor, optimization studies of compounds structurally related to (Z)-N-{4'-[(4,4-difluoro-5-carbamoylmethylidene-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbon-yl]phenyl}carboxamide were performed. The synthesis and phamacological properties of these compounds are described. We first investigated the effect of the carboxamide moiety, and found that a 2-methylfuran-3-carbonyl group at this position increased V-1A binding affinity and selectivity for the V-1A receptor versus the V-2 receptor. The amino group of the 5-carbamoylmethylidene moiety was also examined, and a 4-piperidinopiperidino group was found to be optimal at this position. The hemifumarate of compound 121 (YM218) was shown to exhibit potent binding affinity, V-1A receptor selectivity, and in vivo antagonist activity. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.10.035

文献信息

• Piperazine and piperidine biaryl derivatives
  申请人：Lu Jian Rong

  公开号：US20070259879A1

  公开（公告）日：2007-11-08

  This invention relates to piperazine and piperidine biaryl compounds of Formula (I): or a pharmaceutically acceptable prodrug, salt, polymorph, solvate, enantiomer, diastereomer, racemate, mixture of stereoisomers thereof, or derivative thereof; and to processes for preparing the compounds or pharmaceutical compositions containing the same. The compounds and pharmaceutical compositions of the present invention are provided for use in the treatment of HIV infection and/or AIDS.

  本发明涉及公式（I）的哌嗪和哌啶双芳基化合物： 或其药物可接受的前药、盐、多晶形、溶剂化物、对映体、非对映体、外消旋体、其立体异构体混合物或衍生物；以及用于制备化合物或含有相同化合物的制药组合物的过程。本发明的化合物和制剂用于治疗HIV感染和/或艾滋病。
• HYDROXY CONTAINING FXR (NR1H4) MODULATING COMPOUNDS
  申请人：Gilead Sciences, Inc.

  公开号：US20160176861A1

  公开（公告）日：2016-06-23

  The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.

  本发明涉及与NR1H4受体（FXR）结合并作为FXR激动剂的化合物。本发明进一步涉及利用这些化合物制备药物，通过这些化合物与该核受体结合治疗疾病和/或病况，以及制备这些化合物的合成过程。
• US9751874B2
  申请人：——

  公开号：US9751874B2

  公开（公告）日：2017-09-05
• Synthesis and biological activity of novel 4,4-difluorobenzazepine derivatives as non-peptide antagonists of the arginine vasopressin V1A receptor
  作者：Yoshiaki Shimada、Nobuaki Taniguchi、Akira Matsuhisa、Hiroaki Akane、Noriyuki Kawano、Takeshi Suzuki、Takahiko Tobe、Akio Kakefuda、Takeyuki Yatsu、Atsuo Tahara、Yuichi Tomura、Toshiyuki Kusayama、Koh-ichi Wada、Junko Tsukada、Masaya Orita、Takashi Tsunoda、Akihiro Tanaka

  DOI：10.1016/j.bmc.2005.10.035

  日期：2006.3

  To find potent and selective antagonists of the arginine vasopressin (AVP) V-1A receptor, optimization studies of compounds structurally related to (Z)-N-4'-[(4,4-difluoro-5-carbamoylmethylidene-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbon-yl]phenyl}carboxamide were performed. The synthesis and phamacological properties of these compounds are described. We first investigated the effect of the carboxamide moiety, and found that a 2-methylfuran-3-carbonyl group at this position increased V-1A binding affinity and selectivity for the V-1A receptor versus the V-2 receptor. The amino group of the 5-carbamoylmethylidene moiety was also examined, and a 4-piperidinopiperidino group was found to be optimal at this position. The hemifumarate of compound 121 (YM218) was shown to exhibit potent binding affinity, V-1A receptor selectivity, and in vivo antagonist activity. (c) 2005 Elsevier Ltd. All rights reserved.